Skip the wait and schedule your appointments online or through MyChart.

RSV (Respiratory Syncytial Virus) season: What parents need to know

Research & Innovation

Head and Neck Clinical Trials

Clinical Trials

Merck MK-3475-689-03

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)

Physician & Study Coordinator


Dr. Dhwani Pandya

Study Coordinator

Angela Rankin RN



Synopsis: The purpose of this Study is to test the safety of the study drug, pembroluzimab (MK-3475), and test how your cancer responds to one of the following: pembroluzimab plus radiation therapy (RT) with or without cisplatin after surgery or RT with or without cisplatin after surgery.


Eligibility Criteria
  • Is ≥18 years of age, at the time of signing the informed consent
  • Histologically confirmed new diagnosis of resectable, non-metastatic, squamous cell carcinoma - Clinical stage III oropharyngeal p16 positive that is T4 (N0-N2) M0, OR stage III or IVA oropharyngeal p16 negative, OR Stage III or IVA larynx, hypopharynx, oral cavity (independent of p16)
  • Patients must be eligible for primary surgery as validated by members of a multidisciplinary team
  • PD-L1 testing will be confirmed by a central lab during screening